If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Cardinal Health (CAH) . This company, which is in the Zacks Medical - Dental Supplies industry, shows potential for another earnings beat. This prescription drug distributor has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters ...

Cardinal Health Inc. (CAH) is well-poised for growth, given its long-term supply agreements, diversified product portfolio and strong quarterly earnings. However, the possibility of losing a major customer remains a risk.Shares of this Zacks Rank #2 (Buy) company have risen 12.7% in the past year compared with the industry’s 1.5% growth. The S&P 500 Index has gained 26.2% in the same time frame. CAH, with a market capitalization of $28.62 billion, is a nationwide drug distributor and service provider to pha ...

Dublin, Dec. 30, 2024 (GLOBE NEWSWIRE) -- The "Canada Personal Protective Equipment Market Outlook to 2033 - Gloves, Gowns, Masks, Shoe Covers and Others" report has been added to ResearchAndMarkets.com's offering.The "Canada Personal Protective Equipment Market Outlook to 2033" is a comprehensive databook report, covering key market data on the Canada Personal Protective Equipment market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Examination ...

The most recent trading session ended with Cardinal Health (CAH) standing at $118.83, reflecting a +0.41% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 1.1%. Meanwhile, the Dow gained 0.91%, and the Nasdaq, a tech-heavy index, added 1.35%.Shares of the prescription drug distributor have depreciated by 2.81% over the course of the past month, outperforming the Medical sector's loss of 3.78% and lagging the S&P 500's gain of 0.22%.Investors will be eagerly watchi ...

DUBLIN, Ohio, Dec. 19, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2025 on January 30, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be available on ...

核心观点 - 文章讨论了价值投资策略，并重点介绍了Cardinal Health (CAH) 和 McKesson (MCK) 两家公司，认为它们是目前市场上被低估的价值股 [2][3][4][7] 价值投资策略 - 价值投资是一种通过分析关键估值指标来寻找被低估股票的策略 [2] - Zacks的Style Scores系统用于识别具有特定特征的股票，例如在“价值”类别中获得高分的股票 [3] Cardinal Health (CAH) - CAH目前拥有Zacks Rank 2 (Buy) 和 A级价值评分 [4] - CAH的Forward P/E比率为14.40，低于行业平均的17.29 [4] - CAH的PEG比率为1.41，低于行业平均的1.97 [5] - CAH的P/CF比率为14.47，低于行业平均的18.48 [6] McKesson (MCK) - MCK拥有Zacks Rank 1 (Strong Buy) 和 A级价值评分 [7] - MCK的Forward P/E比率为16.24，低于行业平均的17.29 [7] - MCK的PEG比率为1.15，低于行业平均的1.97 [7] - MCK的P/B比率为-27.69，与行业平均的4.56相比显著不同 [8] 行业比较 - CAH和MCK的估值指标（如Forward P/E、PEG、P/CF、P/B）均低于或显著不同于行业平均水平，表明它们可能被低估 [4][5][6][7][8] 结论 - CAH和MCK的多个关键估值指标显示它们目前可能被低估，具有潜在的投资价值 [9]

Cardinal Health Inc. (CAH) is well-poised for growth, given its acquisition-driven strategy, a diversified product portfolio and a robust pharmaceutical segment. However, inflationary pressure remains a concern.Shares of this Zacks Rank #2 (Buy) company have risen 24.3% in the year-to-date period compared with the industry’s 4.8% gain. The S&P 500 Index has gained 27.1% in the same time frame.         CAH, with a market capitalization of $29.83 billion, is a nationwide drug distributor and service provider ...

Cardinal Health, Inc. (NYSE:CAH) Citi's 2024 Global Healthcare Conference Call December 3, 2024 8:00 AM ET Company Participants Aaron Alt - Chief Financial Officer Matt Sims - Head, Investor Relations Conference Call Participants Daniel Grosslight - Citi Daniel Grosslight Thanks for joining us for the Cardinal Health fireside chat here at Citi's Global Healthcare Conference. My name is Daniel Grosslight. For those of you who don't know me, I'm the health tech and distribution analyst here at Citi. I'm very ...

1. 会议基本信息 - **公司**：Cardinal Health, Inc. (NYSE:CAH) - **会议名称**：Citi's 2024 Global Healthcare Conference Call - **日期**：2024年12月3日 - **时间**：上午8:00 AM ET - **参与者**： - Aaron Alt - 首席财务官 - Matt Sims - 投资关系负责人 - Daniel Grosslight - Citi健康科技和分销分析师 2. 会议主题 - **讨论焦点**：新政府可能对Cardinal Health业务的影响，包括关税和制药业务。 3. 核心观点和论据 - **政治影响**：讨论了新政府可能对Cardinal Health业务的影响，包括关税和制药业务。 - **关税问题**：提及了中美、墨西哥、加拿大以及BRICS国家的潜在关税问题。 4. 其他重要内容 - **会议主持人**：Daniel Grosslight，Citi健康科技和分销分析师 - **公司代表**：Aaron Alt和Matt Sims - **会议目的**：分析新政府可能对Cardinal Health业务的影响，并探讨相关策略。

Cardinal Health (CAH) recently launched the Kendall SCD SmartFlow Compression System in the United States. The system is the next generation of the Kendall Compression Series, offering an enhanced clinician and patient experience.Kendall SCD SmartFlow Compression System is designed to help prevent venous thromboembolism events, enhance blood circulation and treat pain and swelling related to venous stasis.Likely Trend of CAH Stock Following the NewsFollowing the announcement, shares of the company moved mov ...